Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04065074 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip
A Phase 2 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04065074 is a Phase 2 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT04065074, a Phase 2 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a multi-center, single-arm, open-label study of FX006 in patients with hip OA. A maximum number of approximately 30 patients may be enrolled in this protocol. All enrolled patients will receive a single intra-articular (IA) injection of FX006.
Interventions
- DRUG FX006 32 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04065074
The ClinicalTrials.gov registry entry for NCT04065074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FX006 32 mg is the first listed.
NCT04065074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04065074 about?
NCT04065074 is a clinical study titled "Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip". This is a multi-center, single-arm, open-label study of FX006 in patients with hip OA. A maximum number of approximately 30 patients may be enrolled in this protocol. All enrolled patients will receive a single intra-articular (IA) injection of FX006.
What is the current status of trial NCT04065074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2019-07-30. Estimated completion is 2019-12-30.
What interventions are being tested in trial NCT04065074?
The interventions under investigation include: FX006 32 mg (DRUG).
Who is sponsoring clinical trial NCT04065074?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.